Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)

Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)

Overview

Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2), encoded by the [NFE2L2](/genes/nfe2l2) gene, is the master transcriptional regulator of antioxidant response and cellular defense. Nrf2 coordinates the expression of over 200 genes involved in oxidative stress protection, metabolism, detoxification, and mitochondrial function. It is a critical therapeutic target for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/als), and other neurodegenerative disorders.

Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)

Overview

Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2), encoded by the [NFE2L2](/genes/nfe2l2) gene, is the master transcriptional regulator of antioxidant response and cellular defense. Nrf2 coordinates the expression of over 200 genes involved in oxidative stress protection, metabolism, detoxification, and mitochondrial function. It is a critical therapeutic target for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/als), and other neurodegenerative disorders.

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#f8f9fa;text-align:center;font-size:1.1em;">Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)</th></tr>
<tr><td><b>Gene</b></td><td>[NFE2L2](/genes/nfe2l2)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q16236](https://www.uniprot.org/uniprot/Q16236)</td></tr>
<tr><td><b>PDB Structure IDs</b></td><td>2FLU, 3ZGC, 4UDD, 5CGJ</td></tr>
<tr><td><b>Molecular Weight</b></td><td>60,300 Da (full-length)</td></tr>
<tr><td><b>Length</b></td><td>605 amino acids</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Cytoplasm (basal); nucleus (active)</td></tr>
<tr><td><b>Protein Family</b></td><td>CNC-bZIP family (Nrf1, Nrf2, Nrf3, Bach1, Bach2)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">ATHEROSCLEROSIS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">2185 edges</a></td>
</tr>
</table>
</div>

Pathway / Mechanism Diagram

Structure

Nrf2 is a 605-amino acid transcription factor belonging to the CNC-bZIP family (Cap'n'Collar, alongside Nrf1, Nrf3, Bach1, Bach2). The protein contains 7 conserved Neh (Nrf2-ECH) domains that serve distinct functional roles:

Domain Architecture

| Domain | Amino Acids | Function |
|--------|-------------|----------|
| Neh1 | 86-163 | CNC-bZIP for DNA binding, heterodimerization with small Maf |
| Neh2 | 165-318 | Transactivation domain, contains KEAP1-binding motifs (ETGE, DLG) |
| Neh3 | 323-430 | Transactivation domain, recruits coactivators |
| Neh4 | 431-500 | Transactivation domain, recruits coactivators ( CBP/p300) |
| Neh5 | 501-561 | Transactivation domain, acidic region |
| Neh6 | 562-605 | Multidomain, regulates nuclear accumulation |
| Neh7 | 1-85 | BTB-like domain, negative regulation |

KEAP1-Binding Motifs

The Neh2 domain contains two key motifs that mediate KEAP1 interaction:

• ETGE motif (residues 79-82): High-affinity KEAP1 binding
• DLG motif (residues 79-82): Low-affinity KEAP1 binding

Normal Function

The KEAP1-Nrf2 Pathway

Under basal (non-stress) conditions, Nrf2 is continuously sequestered in the cytoplasm by KEAP1 (Kelch-like ECH-associated protein 1), a cysteine-rich adaptor protein that functions as an E3 ubiquitin ligase substrate adaptor. KEAP1 targets Nrf2 for ubiquitination and proteasomal degradation, maintaining low Nrf2 levels (half-life ~15-30 minutes).

Upon oxidative stress, cysteine residues on KEAP1 (particularly C151, C273, C288) are oxidized, undergoing conformational changes that prevent Nrf2 ubiquitation. This releases Nrf2, which translocates to the nucleus.

Transcriptional Activation

In the nucleus, Nrf2 forms heterodimers with small Maf proteins (MAFK, MAFF, MAFG) and binds to the Antioxidant Response Element (ARE) sequence (5'-TGACnnnGC-3') in the promoter regions of target genes. This activates a battery of protective genes including:

• Phase II detoxification: NQO1, HMOX1, GST
• Antioxidant enzymes: SOD, CAT, GPX2, PRDX1
• Mitochondrial function: TFAM, PGC-1α
• Proteostasis: SQSTM1/p62, Hsp70, UPS components
• Inflammation: Anti-inflammatory mediators

Target Gene Network

Nrf2 regulates genes involved in:

• Glutathione synthesis and metabolism
• Drug detoxification (cytochrome P450-independent)
• Iron metabolism (ferritin)
• Heme metabolism
• Mitochondrial biogenesis
• Autophagy and proteasomal degradation
• DNA repair

Role in Neurodegeneration

Aging and Nrf2 Decline

Nrf2 activity declines with normal aging, and this decline is accelerated in neurodegenerative diseases. Several mechanisms contribute:

Alzheimer's Disease

In [Alzheimer's disease](/diseases/alzheimers-disease), Nrf2 signaling is impaired at multiple levels:

• [Aβ](/proteins/amyloid-beta) oligomers inhibit Nrf2 nuclear translocation
• [Tau](/proteins/tau) pathology sequesters Nrf2 in the cytoplasm
• Oxidative stress overwhelms Nrf2 protective capacity
• KEAP1 oxidized (C151) loses ability to sequester Nrf2

• Reduces Aβ-induced neurotoxicity
• Improves synaptic function
• Decreases neuroinflammation
• Enhances mitochondrial function

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), Nrf2 deficiency is particularly pronounced:

• [Dopamine](/entities/dopamine) metabolism generates high levels of reactive oxygen species
• Lewy bodies contain oxidized proteins that overwhelm Nrf2
• SNCA (α-synuclein) aggregation impairs Nrf2 function
• Genetic risk factors (LRRK2 G2019S) affect stress response

• Reduce oxidative damage
• Improve mitochondrial function
• Decrease neuroinflammation

Amyotrophic Lateral Sclerosis

In [ALS](/diseases/amyotrophic-lateral-sclerosis), Nrf2 signaling is dysregulated:

• SOD1 mutations cause oxidative stress
• C9orf72 expansions affect stress granule dynamics
• TDP-43 pathology disrupts transcriptional regulation

[@chen2022]

Huntington's Disease

In [Huntington's disease](/diseases/huntingtons), Nrf2 activity is reduced:

• Mutant huntingtin impairs Nrf2 transcriptional activity
• Reduced expression of antioxidant genes
• Mitochondrial dysfunction

Therapeutic Targeting

Nrf2 Activators

Several classes of Nrf2 activators are in development:

| Compound | Class | Mechanism | Status | Disease |
|----------|------|-----------|--------|---------|
| Bardoxolone methyl | CDDO-Im | Covalent KEAP1 inhibitor | Phase 2/3 | AD, CKD |
| Sulforaphane | Isothiocyanate | Covalent KEAP1 inhibitor | Phase 1/2 | PD, AD |
| Oltipraz | Dithiolopyrrolone | Nrf2 stabilizer | Phase 2 | Cancer |
| Dimethyl fumarate | Electrophile | KEAP1 modifier | Approved | MS |
| CDDO-Me | Synthetic triterpenoid | KEAP1 inhibitor | Phase 2 | AD |

Mechanism of Action

Clinical Trials

BARDOXOLONE METHYL (CDDO-Im):

• LIGHTS (NCT01344460): Phase 2 in AD - completed, showed mixed results
• SUSTAIN (NCT03302728): Phase 2 follow-up - ongoing

• Phase 1 trials in PD completed: safety established
• Phase 2 trials planned in early PD

Signaling Pathways

Cross-talk with Other Pathways

┌──────────────────────────────────────┐
│ Nrf2 Activation │
└──────────────────────────────────────┘
│
┌───────────────────────────┬─┴─┬───────────────────────────┐
│ │ │ │
▼ ▼ ▼ ▼
┌─────────────────┐ ┌─────────────────┐ ┌─────────────────┐
│ NF-κB │◄──►│ Nrf2 │◄──►│ p53 │
│ inflammation │ │ antioxidant │ │ stress │
└─────────────────┘ └─────────────────┘ └─────────────────┘
│ │ │
▼ ▼ ▼
┌─────────────────┐ ┌─────────────────┐ ┌─────────────────┐
│ Pro-inflammatory│ │ Mitochondrial │ │ Cell cycle │
│ gene expression│ │ biogenesis │ │ regulation │
└─────────────────┘ └─────────────────┘ └─────────────────┘

Interactions

• NF-κB pathway: Nrf2 and NF-κB reciprocally inhibit each other
• p53 pathway: Cross-talk at transcriptional level
• MAPK pathways: Nrf2 is phosphorylated by MAPKs (regulates activity)
• PI3K/Akt pathway: Akt phosphorylation enhances Nrf2 activity
• AMPK pathway: Energy stress activates Nrf2

Biomarkers

Nrf2 Activity as Biomarker

• mRNA expression of NRF2 target genes in blood/CSF: NQO1, HMOX1, GCLC
• Nuclear Nrf2 levels: Peripheral blood mononuclear cells
• Serum oxidative stress markers: Correlate with Nrf2 activity

Animal Models

| Model | Application | Reference |
|------|------------|-----------|
| Nrf2 knockout mice | Nrf2 role in neurodegeneration | [@kensler2007] |
| KEAP1 knockout mice | Constitutive Nrf2 activation | [@yamamoto2018] |
| Transgenic Nrf2 overexpression | Nrf2 therapeutic potential | [@gao2021] |
| Conditional Nrf2 mice | Cell-type specific studies | [@cuadrado2019] |

Research Directions

Emerging Areas

Challenges

• Brain penetration: Many Nrf2 activators don't cross BBB
• Target specificity: Off-target effects due to electrophilicity
• Dosing: Chronic vs. acute activation has different effects
• Biomarkers: Need better Nrf2 activity biomarkers

Genetic Associations

NFE2L2 Polymorphisms

| SNP | Effect | Disease Association |
|-----|-------|---------------------|
| rs6721961 (promoter) | Reduced Nrf2 expression | PD risk |
| rs2886158 | Altered Nrf2 activity | AD risk |
| rs2001823 | Modified oxidative stress response | ALS risk |

Cross-Linking

Related Proteins

• [KEAP1](/proteins/keap1-protein) — Nrf2 adaptor/ ubiquitin ligase substrate
• [MAFK](/proteins/maf-k-protein) — Nrf2 heterodimer partner
• [P62](/proteins/sqstm1) — Nrf2 target, feedback regulator
• [HO-1](/proteins/ho-1) — Nrf2 target enzyme
• [NQO1](/proteins/nqo1-protein) — Nrf2 target enzyme

Related Mechanisms

• [Oxidative Stress Pathway](/mechanisms/oxidative-stress)
• [Protein Quality Control](/mechanisms/protein-quality-control)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)
• [Neuroinflammation](/mechanisms/neuroinflammation)

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/als)
• [Huntington's Disease](/diseases/huntingtons)

See Also

• [NFE2L2 Gene](/genes/nfe2l2)
• [KEAP1 Gene](/genes/keap1)
• [Oxidative Stress Pathway](/mechanisms/oxidative-stress)
• [Protein Quality Control](/mechanisms/protein-quality-control)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/als)

External Links

• [UniProt: Q16236](https://www.uniprot.org/uniprot/Q16236)
• [NCBI Gene: 4780](https://www.ncbi.nlm.nih.gov/gene/4780)
• [KEAP1-Nrf2 Pathway: Wikipedia](https://en.wikipedia.org/wiki/KEAP1-Nrf2_pathway)
• [KEAP1-Nrf2 Pathway Database](https://www.phosphosite.org/pages/keap1_nrf2_pathway)

References